Zealand Pharma has several big obesity drug trial readouts coming soon, and a new partnership with Roche could help turn any good results into real-world reach. But the company’s future still hinges on trial success, fierce competition, and how much pricing pressure hits weight‑loss medicines.Read more
Key Takeaways Differentiated obesity pipeline, strategic partnerships, and robust real-world efficacy set Zealand Pharma to outpace market growth and competitor expectations in metabolic diseases. Capital-efficient R&D and broad program scope position the company for rapid label expansion, high patient adherence, and durable, outsized recurring revenues.Read more
Catalysts About Zealand Pharma Zealand Pharma is a biotech company developing peptide based therapies for obesity, metabolic and rare diseases, largely through late stage partnerships with major pharmaceutical companies. What are the underlying business or industry changes driving this perspective?Read more
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
